JP2015524837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524837A5 JP2015524837A5 JP2015527028A JP2015527028A JP2015524837A5 JP 2015524837 A5 JP2015524837 A5 JP 2015524837A5 JP 2015527028 A JP2015527028 A JP 2015527028A JP 2015527028 A JP2015527028 A JP 2015527028A JP 2015524837 A5 JP2015524837 A5 JP 2015524837A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- amino
- ureido
- oxy
- naphthalen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- -1 2-morpholinoethyl Chemical group 0.000 claims 5
- 125000005275 alkylenearyl group Chemical group 0.000 claims 5
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 208000002691 Choroiditis Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 206010022941 Iridocyclitis Diseases 0.000 claims 3
- 208000003971 Posterior uveitis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 201000004612 anterior uveitis Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 201000007407 panuveitis Diseases 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- YARHUYMJLJCURZ-UHFFFAOYSA-N 3-methoxy-5-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C(=O)NCCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)C)=NN1C1=CC=C(C)C=C1 YARHUYMJLJCURZ-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000029771 childhood onset asthma Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- BOBQDWLSTCDSET-UHFFFAOYSA-N 1-[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]-3-naphthalen-1-ylurea Chemical compound C(C)(C)C1=NN(C(=C1)NC(NC1=CC=CC2=CC=CC=C12)=O)C1=CC=C(C=C1)C BOBQDWLSTCDSET-UHFFFAOYSA-N 0.000 claims 1
- FGBHWWCXGQAKAZ-UHFFFAOYSA-N 1-[4-[2-[3-methoxy-5-(morpholine-4-carbonyl)anilino]pyrimidin-4-yl]oxynaphthalen-1-yl]-3-[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]urea Chemical compound C=1C(C(=O)N2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)C)=NN1C1=CC=C(C)C=C1 FGBHWWCXGQAKAZ-UHFFFAOYSA-N 0.000 claims 1
- BANXPZGDYGVXOC-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-[3-(morpholine-4-carbonyl)anilino]pyrimidin-4-yl]oxynaphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=CC=4)C(=O)N4CCOCC4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 BANXPZGDYGVXOC-UHFFFAOYSA-N 0.000 claims 1
- OJKGJLKJOICLKA-UHFFFAOYSA-N 2-methoxy-5-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=C(C(=O)NCCN2CCOCC2)C(OC)=CC=C1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)C)=NN1C1=CC=C(C)C=C1 OJKGJLKJOICLKA-UHFFFAOYSA-N 0.000 claims 1
- QMMSRYDOEGIITQ-UHFFFAOYSA-N 3-[[4-[2,3-dichloro-4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]phenoxy]pyrimidin-2-yl]amino]-5-ethynyl-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(N=1)=CC=NC=1NC(C=1)=CC(C#C)=CC=1C(=O)NCCN1CCOCC1 QMMSRYDOEGIITQ-UHFFFAOYSA-N 0.000 claims 1
- XCGWAOXDKPENDE-UHFFFAOYSA-N 3-[[4-[2,3-dichloro-4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]phenoxy]pyrimidin-2-yl]amino]-5-ethynylbenzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(N=1)=CC=NC=1NC1=CC(C#C)=CC(C(N)=O)=C1 XCGWAOXDKPENDE-UHFFFAOYSA-N 0.000 claims 1
- BWZYTKHNTXQKBP-UHFFFAOYSA-N 3-[[4-[2,3-dichloro-4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]phenoxy]pyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-5-ethynylbenzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)NC(C(=C1Cl)Cl)=CC=C1OC(N=1)=CC=NC=1NC1=CC(C#C)=CC(C(=O)NCCN(C)C)=C1 BWZYTKHNTXQKBP-UHFFFAOYSA-N 0.000 claims 1
- PURPJUPEELMKNM-UHFFFAOYSA-N 3-[[4-[2,3-difluoro-4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]phenoxy]pyrimidin-2-yl]amino]-5-ethynyl-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)NC(C(=C1F)F)=CC=C1OC(N=1)=CC=NC=1NC(C=1)=CC(C#C)=CC=1C(=O)NCCN1CCOCC1 PURPJUPEELMKNM-UHFFFAOYSA-N 0.000 claims 1
- WLXUDQMWNQFZOR-UHFFFAOYSA-N 3-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-methyl-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(C)C=4)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)C)=N1 WLXUDQMWNQFZOR-UHFFFAOYSA-N 0.000 claims 1
- UDVSRXQVDHWZAL-UHFFFAOYSA-N 3-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=CC=4)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)C)=N1 UDVSRXQVDHWZAL-UHFFFAOYSA-N 0.000 claims 1
- CZNVSHUEQYXNKX-UHFFFAOYSA-N 3-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)-5-(trifluoromethyl)benzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC(N=1)=CC=NC=1NC(C=C(C=1)C(F)(F)F)=CC=1C(=O)NCCN1CCOCC1 CZNVSHUEQYXNKX-UHFFFAOYSA-N 0.000 claims 1
- DQLUUNQMRQJPAL-UHFFFAOYSA-N 3-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC(N=1)=CC=NC=1NC(C=1)=CC=CC=1C(=O)NCCN1CCOCC1 DQLUUNQMRQJPAL-UHFFFAOYSA-N 0.000 claims 1
- ZOBKJVAECISXJA-UHFFFAOYSA-N 3-[[4-[4-[[5-cyclopropyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-methoxy-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C(=O)NCCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C2CC2)=NN1C1=CC=C(C)C=C1 ZOBKJVAECISXJA-UHFFFAOYSA-N 0.000 claims 1
- KKBSRZBNVASLTJ-UHFFFAOYSA-N 3-[[4-[4-[[5-ethyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-methoxy-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(CC)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC(N=1)=CC=NC=1NC(C=1)=CC(OC)=CC=1C(=O)NCCN1CCOCC1 KKBSRZBNVASLTJ-UHFFFAOYSA-N 0.000 claims 1
- RIGZTRRKOZWKPG-SANMLTNESA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-ethynyl-n-[(2s)-1-methoxypropan-2-yl]benzamide Chemical compound C#CC1=CC(C(=O)N[C@@H](C)COC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(OC)=CC=4)=CC=3)C=CN=2)=C1 RIGZTRRKOZWKPG-SANMLTNESA-N 0.000 claims 1
- HHONORFVXLXKEB-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(OC)C=4)C(N)=O)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 HHONORFVXLXKEB-UHFFFAOYSA-N 0.000 claims 1
- BEMAXRGCROABFF-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-propylbenzamide Chemical compound CCCNC(=O)C1=CC=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(OC)=CC=4)=CC=3)C=CN=2)=C1 BEMAXRGCROABFF-UHFFFAOYSA-N 0.000 claims 1
- VWGMFKBQYRNIIN-PMERELPUSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-ethynyl-n-[(2s)-1-morpholin-4-ylpropan-2-yl]benzamide Chemical compound C([C@H](C)NC(=O)C=1C=C(C=C(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)C=1)C#C)N1CCOCC1 VWGMFKBQYRNIIN-PMERELPUSA-N 0.000 claims 1
- URRPWKVYUYOQBW-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-methylbenzamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(C)C=4)C(N)=O)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 URRPWKVYUYOQBW-UHFFFAOYSA-N 0.000 claims 1
- XZCLCFIAUCVNJF-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 XZCLCFIAUCVNJF-UHFFFAOYSA-N 0.000 claims 1
- JTERLHICJVJIRK-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-hydroxyethyl)-4-methoxybenzamide Chemical compound COC1=CC=C(C(=O)NCCO)C=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 JTERLHICJVJIRK-UHFFFAOYSA-N 0.000 claims 1
- LHYKFLNJIXCRLM-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-hydroxyethyl)-5-methoxybenzamide Chemical compound OCCNC(=O)C1=CC(OC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 LHYKFLNJIXCRLM-UHFFFAOYSA-N 0.000 claims 1
- OHZMBBAXCDRXLC-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-4-methoxybenzamide Chemical compound COC1=CC=C(C(=O)NCCN(C)C)C=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 OHZMBBAXCDRXLC-UHFFFAOYSA-N 0.000 claims 1
- OCGMYHIDTHTZSV-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-5-methoxybenzamide Chemical compound CN(C)CCNC(=O)C1=CC(OC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 OCGMYHIDTHTZSV-UHFFFAOYSA-N 0.000 claims 1
- GHRBLHUQTOTLMU-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 GHRBLHUQTOTLMU-UHFFFAOYSA-N 0.000 claims 1
- HOBGSWDBYMRRJR-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(4-methylthiophen-2-yl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound CC1=CSC(N2C(=CC(=N2)C(C)(C)C)NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=CC=4)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=C1 HOBGSWDBYMRRJR-UHFFFAOYSA-N 0.000 claims 1
- GAJUUQYPFUJQCH-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(6-methoxypyridin-3-yl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-ethynyl-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=NC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(C=4)C#C)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 GAJUUQYPFUJQCH-UHFFFAOYSA-N 0.000 claims 1
- DTYGFXKVLYKJLW-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-(6-methoxypyridin-3-yl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-methoxy-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C(=O)NCCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(OC)N=C1 DTYGFXKVLYKJLW-UHFFFAOYSA-N 0.000 claims 1
- LMFUUSCWSNKGAY-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-2-[4-(dimethylamino)phenyl]pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-ethynyl-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(N(C)C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(C=4)C#C)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 LMFUUSCWSNKGAY-UHFFFAOYSA-N 0.000 claims 1
- DDKIKSYBXRUQAD-UHFFFAOYSA-N 3-[[6-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-4-yl]amino]-5-methoxy-N-(2-morpholin-4-ylethyl)benzamide Chemical compound COC1=CC=C(C=C1)N1N=C(C=C1NC(=O)NC1=C2C=CC=CC2=C(OC2=CC(NC3=CC(=CC(OC)=C3)C(=O)NCCN3CCOCC3)=NC=N2)C=C1)C(C)(C)C DDKIKSYBXRUQAD-UHFFFAOYSA-N 0.000 claims 1
- RQRUNCDCHJDCDE-UHFFFAOYSA-N 3-bromo-5-[[4-[4-[[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(Br)C=4)C(N)=O)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 RQRUNCDCHJDCDE-UHFFFAOYSA-N 0.000 claims 1
- QGRUEQPBBBTRPN-UHFFFAOYSA-N 3-bromo-5-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(Br)C=4)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)(C)C)=N1 QGRUEQPBBBTRPN-UHFFFAOYSA-N 0.000 claims 1
- LKZAFVLIMSKDQX-UHFFFAOYSA-N 3-ethynyl-5-[[4-[4-[[2-(4-methylphenyl)-5-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(C=4)C#C)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)(C)C(F)(F)F)=N1 LKZAFVLIMSKDQX-UHFFFAOYSA-N 0.000 claims 1
- BRMHQJDIOQPLGE-UHFFFAOYSA-N 3-ethynyl-5-[[4-[4-[[2-(4-methylphenyl)-5-(1,1,2,2,2-pentafluoroethyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(C=4)C#C)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(F)(F)C(F)(F)F)=N1 BRMHQJDIOQPLGE-UHFFFAOYSA-N 0.000 claims 1
- CSZJFFGJPPIFRZ-UHFFFAOYSA-N 3-ethynyl-5-[[4-[4-[[5-(2-isocyanopropan-2-yl)-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-N-(2-morpholin-4-ylethyl)benzamide Chemical compound Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3cc(cc(c3)C(=O)NCCN3CCOCC3)C#C)n2)c2ccccc12)C(C)(C)[N+]#[C-] CSZJFFGJPPIFRZ-UHFFFAOYSA-N 0.000 claims 1
- JQVRXEMLYFQYRR-UHFFFAOYSA-N 3-methoxy-4-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound COC1=CC(C(=O)NCCN2CCOCC2)=CC=C1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)C)=NN1C1=CC=C(C)C=C1 JQVRXEMLYFQYRR-UHFFFAOYSA-N 0.000 claims 1
- URPHWXWGWHZRLT-UHFFFAOYSA-N 3-methoxy-5-[[4-[4-[[2-(4-methoxyphenyl)-5-prop-1-en-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(OC)C=4)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)=C)=N1 URPHWXWGWHZRLT-UHFFFAOYSA-N 0.000 claims 1
- BZPKVUCAGBEWOQ-UHFFFAOYSA-N 3-methoxy-5-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyridin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3C=C(NC=4C=C(C=C(OC)C=4)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)C)=N1 BZPKVUCAGBEWOQ-UHFFFAOYSA-N 0.000 claims 1
- USUSRWRXNKNUGL-UHFFFAOYSA-N 3-methoxy-5-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(OC)C=4)C(=O)NCCN4CCOCC4)N=CC=3)=CC=2)=CC(C(C)C)=N1 USUSRWRXNKNUGL-UHFFFAOYSA-N 0.000 claims 1
- HUMIGOFJWQKXPY-UHFFFAOYSA-N 3-methoxy-5-[[4-[4-[[2-(4-methylphenyl)-5-(1,1,2,2,2-pentafluoroethyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C(=O)NCCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(F)(F)C(F)(F)F)=NN1C1=CC=C(C)C=C1 HUMIGOFJWQKXPY-UHFFFAOYSA-N 0.000 claims 1
- HTMINSIGYJFGEU-UHFFFAOYSA-N 3-methoxy-5-[[4-[4-[[2-(4-methylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C(=O)NCCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(F)(F)F)=NN1C1=CC=C(C)C=C1 HTMINSIGYJFGEU-UHFFFAOYSA-N 0.000 claims 1
- WQOAQFRQXWKXRO-UHFFFAOYSA-N 3-methoxy-5-[[6-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-4-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C(=O)NCCN2CCOCC2)=CC(OC)=CC=1NC(N=CN=1)=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)C)=NN1C1=CC=C(C)C=C1 WQOAQFRQXWKXRO-UHFFFAOYSA-N 0.000 claims 1
- QHHCOZDURKDLDL-UHFFFAOYSA-N 3-methoxy-n-(2-methoxyethyl)-5-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NCCOC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)C)C=4C=CC(OC)=CC=4)=CC=3)C=CN=2)=C1 QHHCOZDURKDLDL-UHFFFAOYSA-N 0.000 claims 1
- OOJMGPZKNVMKBS-UHFFFAOYSA-N 3-methoxy-n-(2-methoxyethyl)-5-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NCCOC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 OOJMGPZKNVMKBS-UHFFFAOYSA-N 0.000 claims 1
- PDFAYXCJHTYGHT-UHFFFAOYSA-N 3-methoxy-n-methyl-5-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C(C(=O)N(C)CCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)C)=NN1C1=CC=C(C)C=C1 PDFAYXCJHTYGHT-UHFFFAOYSA-N 0.000 claims 1
- IHERTXREJRKYHR-UHFFFAOYSA-N 3-methyl-5-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC(N=1)=CC=NC=1NC(C=1)=CC(C)=CC=1C(=O)NCCN1CCOCC1 IHERTXREJRKYHR-UHFFFAOYSA-N 0.000 claims 1
- KQAUXGIFCIXPHN-UHFFFAOYSA-N 4-[[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-hydroxyethyl)-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCO)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 KQAUXGIFCIXPHN-UHFFFAOYSA-N 0.000 claims 1
- WCTNEALHPXRJMI-UHFFFAOYSA-N 4-methoxy-3-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound COC1=CC=C(C(=O)NCCN2CCOCC2)C=C1NC(N=1)=NC=CC=1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)C)=NN1C1=CC=C(C)C=C1 WCTNEALHPXRJMI-UHFFFAOYSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229950004244 laninamivir Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YGZNOUTVUALXEX-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-methoxy-4-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NCCO)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 YGZNOUTVUALXEX-UHFFFAOYSA-N 0.000 claims 1
- WDZOSPABBUJVMV-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-methoxy-5-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(OC)C=4)C(=O)NCCO)N=CC=3)=CC=2)=CC(C(C)C)=N1 WDZOSPABBUJVMV-UHFFFAOYSA-N 0.000 claims 1
- NNHIOWJVALLUAA-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-methoxy-5-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound OCCNC(=O)C1=CC(OC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 NNHIOWJVALLUAA-UHFFFAOYSA-N 0.000 claims 1
- ZGVCPFSIDNPESN-UHFFFAOYSA-N n-(2-hydroxyethyl)-4-methoxy-3-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C(=CC=C(C=4)C(=O)NCCO)OC)N=CC=3)=CC=2)=CC(C(C)C)=N1 ZGVCPFSIDNPESN-UHFFFAOYSA-N 0.000 claims 1
- DYFJXOPTRKATQT-UHFFFAOYSA-N n-(2-hydroxyethyl)-4-methoxy-3-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound COC1=CC=C(C(=O)NCCO)C=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 DYFJXOPTRKATQT-UHFFFAOYSA-N 0.000 claims 1
- PAXVLFZEDPNTNS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-methoxy-4-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound COC1=CC(C(=O)NCCN(C)C)=CC=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 PAXVLFZEDPNTNS-UHFFFAOYSA-N 0.000 claims 1
- XGOUHJLISKQBDN-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-methoxy-5-[[4-[4-[[2-(4-methoxyphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OC=3N=C(NC=4C=C(C=C(OC)C=4)C(=O)NCCN(C)C)N=CC=3)=CC=2)=CC(C(C)C)=N1 XGOUHJLISKQBDN-UHFFFAOYSA-N 0.000 claims 1
- RNGNGIHVGNTTHO-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-methoxy-5-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound CN(C)CCNC(=O)C1=CC(OC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4N(N=C(C=4)C(C)C)C=4C=CC(C)=CC=4)=CC=3)C=CN=2)=C1 RNGNGIHVGNTTHO-UHFFFAOYSA-N 0.000 claims 1
- HSXOEINUWICALJ-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-methoxy-3-[[4-[4-[[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]benzamide Chemical compound COC1=CC=C(C(=O)NCCN(C)C)C=C1NC1=NC=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)C)C=3C=CC(C)=CC=3)=CC=2)=N1 HSXOEINUWICALJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- 229960002194 oseltamivir phosphate Drugs 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims 1
- 229960001084 peramivir Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 150000003512 tertiary amines Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1214750.0 | 2012-08-17 | ||
| GBGB1214750.0A GB201214750D0 (en) | 2012-08-17 | 2012-08-17 | Compounds |
| US201361782793P | 2013-03-14 | 2013-03-14 | |
| US61/782,793 | 2013-03-14 | ||
| PCT/GB2013/052184 WO2014027209A1 (en) | 2012-08-17 | 2013-08-16 | Pyrazolyl-ureas as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524837A JP2015524837A (ja) | 2015-08-27 |
| JP2015524837A5 true JP2015524837A5 (enExample) | 2016-09-23 |
Family
ID=47016978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527028A Pending JP2015524837A (ja) | 2012-08-17 | 2013-08-16 | キナーゼ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140057915A1 (enExample) |
| EP (1) | EP2885284B1 (enExample) |
| JP (1) | JP2015524837A (enExample) |
| KR (1) | KR20150056777A (enExample) |
| CN (1) | CN105073725A (enExample) |
| AU (1) | AU2013303922A1 (enExample) |
| BR (1) | BR112015003218A2 (enExample) |
| CA (1) | CA2881914A1 (enExample) |
| EA (1) | EA025393B1 (enExample) |
| GB (1) | GB201214750D0 (enExample) |
| MX (1) | MX2015002044A (enExample) |
| WO (1) | WO2014027209A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004064817A1 (ja) * | 2003-01-22 | 2004-08-05 | Nichiban Co., Ltd. | 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法 |
| UA105763C2 (uk) | 2007-12-19 | 2014-06-25 | Кансер Рісерч Текнолоджі Лімітед | 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ |
| NZ706154A (en) | 2010-02-01 | 2016-09-30 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| JP2014528404A (ja) | 2011-10-03 | 2014-10-27 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| MX363949B (es) | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Inhibidor de quinasa. |
| US9771353B2 (en) * | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| EP3105222B1 (en) | 2014-02-14 | 2018-04-11 | Respivert Limited | Aromatic heterocyclic compounds as antiinflammatory compounds |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| WO2016196365A1 (en) * | 2015-05-29 | 2016-12-08 | Envisia Therapeutics, Inc. | Implant for treatment of an ocular condition |
| UA127863C2 (uk) * | 2015-12-16 | 2024-01-31 | Локсо Онколоджі, Інк. | Сполуки, які можна застосовувати як інгібітори кінази |
| CA3015978A1 (en) * | 2016-04-06 | 2017-10-12 | Topivert Pharma Limited | Kinase inhibitors |
| WO2017188818A1 (en) * | 2016-04-29 | 2017-11-02 | Enceladus Pharmaceuticals B.V. | Liposomal corticosteroids for topical injection in inflamed lesions or areas |
| CN106771117B (zh) * | 2016-11-25 | 2018-09-14 | 王婧 | 一种中性粒细胞抗原底片的制备方法 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP2021501130A (ja) | 2017-10-05 | 2021-01-14 | フルクラム セラピューティクス，インコーポレイテッド | ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69836563T2 (de) | 1997-12-22 | 2007-05-16 | Bayer Pharmaceuticals Corp., West Haven | INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN |
| DE69834842T2 (de) | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen |
| US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| EP1200411B1 (en) | 1999-07-09 | 2005-12-14 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds |
| JP4955171B2 (ja) | 1999-11-16 | 2012-06-20 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての尿素誘導体 |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| CA2445003A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| ES2284887T3 (es) | 2001-07-11 | 2007-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Metodos para tratar enfermedades transmitidas por citocinas. |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| JP4629978B2 (ja) | 2002-02-25 | 2011-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物 |
| ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
| EP1778686B9 (en) | 2004-08-12 | 2009-07-08 | Pfizer Limited | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| GB0500435D0 (en) | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| PE20070640A1 (es) | 2005-10-28 | 2007-08-10 | Lilly Co Eli | Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38 |
| HUE025197T2 (en) | 2008-03-17 | 2016-02-29 | Ambit Biosciences Corp | Quinazoline derivatives as RAF kinase modulators and methods for their use |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| WO2010067130A1 (en) | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| WO2010072155A1 (zh) | 2008-12-26 | 2010-07-01 | 复旦大学 | 一种嘧啶类衍生物及其制备方法和用途 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| EP2548862B1 (en) | 2010-03-15 | 2016-06-08 | Ube Industries, Ltd. | Method for producing amide compound |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| EP2582700B1 (en) | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| JP2014528404A (ja) | 2011-10-03 | 2014-10-27 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 |
| PE20141370A1 (es) | 2011-12-09 | 2014-10-17 | Chiesi Farma Spa | Inhibidores de quinasa |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| MX363949B (es) | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Inhibidor de quinasa. |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| EP3105222B1 (en) | 2014-02-14 | 2018-04-11 | Respivert Limited | Aromatic heterocyclic compounds as antiinflammatory compounds |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
-
2012
- 2012-08-17 GB GBGB1214750.0A patent/GB201214750D0/en not_active Ceased
-
2013
- 2013-08-16 US US13/969,328 patent/US20140057915A1/en not_active Abandoned
- 2013-08-16 EA EA201590391A patent/EA025393B1/ru not_active IP Right Cessation
- 2013-08-16 KR KR1020157006554A patent/KR20150056777A/ko not_active Withdrawn
- 2013-08-16 JP JP2015527028A patent/JP2015524837A/ja active Pending
- 2013-08-16 EP EP13750934.5A patent/EP2885284B1/en active Active
- 2013-08-16 US US14/422,158 patent/US9701670B2/en not_active Expired - Fee Related
- 2013-08-16 MX MX2015002044A patent/MX2015002044A/es unknown
- 2013-08-16 CN CN201380054166.5A patent/CN105073725A/zh active Pending
- 2013-08-16 AU AU2013303922A patent/AU2013303922A1/en not_active Abandoned
- 2013-08-16 WO PCT/GB2013/052184 patent/WO2014027209A1/en not_active Ceased
- 2013-08-16 BR BR112015003218A patent/BR112015003218A2/pt not_active IP Right Cessation
- 2013-08-16 CA CA2881914A patent/CA2881914A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524837A5 (enExample) | ||
| JP2017505794A5 (enExample) | ||
| AU2014233414B2 (en) | N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| RU2401265C2 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| CN101534904B (zh) | 治疗血小板过量的bcl抑制剂 | |
| US9133183B2 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2017505784A5 (enExample) | ||
| JP2018522823A5 (enExample) | ||
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| RU2016108753A (ru) | Ингибиторы ферментов | |
| JP6251275B2 (ja) | ナトリウムチャンネル阻害剤、その製造方法およびその用途 | |
| JP2016519680A5 (enExample) | ||
| JP2016515606A5 (enExample) | ||
| RU2020140891A (ru) | Производные пиразола в качестве ингибиторов калликреина | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP5782430B2 (ja) | 新規アミド誘導体およびその医薬としての用途 | |
| RU2011137399A (ru) | Гетероциклическое производное | |
| JP2011520896A5 (enExample) | ||
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| JP2013510876A5 (enExample) | ||
| RU2013114352A (ru) | Азабензотиазолы, композиции и способы применения | |
| JP2017502033A5 (enExample) | ||
| RU2013152961A (ru) | Изоксазолины в качестве терапевтических агентов |